Table 3.
Characteristics of the eligible studies in the meta-analysis of weight loss ratio
| Studies | Subsets | Inclusion period | Reported survival (years) | Total patients | Stage | Cutoff value | Treatments |
|---|---|---|---|---|---|---|---|
| Lin et al. | 2006-2012 | 3 | 238 | I-IVb | 5% | RT/CRT | |
| Du et al. | 5%-10%vs.5% | 2003-2006 | 5 | 507 | I-IVb | 5% | RT/CRT |
| Du et al. | 10%vs.5% | 2003-2006 | 5 | 422 | I-IVb | 5% | RT/CRT |
| Shen et al. | Hypo-weight | 2000-2004 | 5 | 212 | I-IVb | 5% | RT/CRT |
| Shen et al. | Normal weight | 2000-2004 | 5 | 1157 | I-IVb | 5% | RT/CRT |
| Shen et al. | Hyper-weight | 2000-2004 | 5 | 1064 | I-IVb | 5% | RT/CRT |
| Zeng et al. | RT plus CCRT | 2001-2005 | 5 | 1374 | I-IVb | 4.60% | RT/CRT |
| Zeng et al. | IMRT | 2001-2005 | 5 | 110 | I-IVb | 4.60% | RT/CRT |
| Primary cohort | 2009-2012 | 4 | 221 | I-IVb | DMFS:5% OS:10% |
CCRT/IC+CCRT |
Abbreviations: RT, radiotherapy; CRT, chemoradiotherapy; CCRT, concurrent chemoradiotherapy; DMFS, distant-metastasis-free survival; IC, induction chemotherapy; IMRT, intensity-modulated radiotherapy